Consun Pharmaceutical Group Limited (HKG:1681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
14.44
+0.26 (1.83%)
Jun 1, 2026, 4:08 PM HKT
Market Cap12.15B +50.3%
Revenue (ttm)3.80B +15.2%
Net Income1.20B +18.4%
EPS1.40 +15.6%
Shares Out 841.55M
PE Ratio10.30
Forward PE8.47
Dividend0.80 (5.64%)
Ex-Dividend DateJun 9, 2026
Volume767,020
Open14.29
Previous Close14.18
Day's Range14.21 - 14.50
52-Week Range10.30 - 19.49
Beta0.54
AnalystsBuy
Price Target23.76 (+64.54%)
Earnings DateAug 20, 2026

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function as... [Read more]

Sector Healthcare
Founded 1997
Employees 3,115
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1681
Full Company Profile

Financial Performance

In 2025, HKG:1681's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY Financial Statements